<DOC>
	<DOC>NCT01967719</DOC>
	<brief_summary>The primary objective of the study is to evaluate the pharmacokinetic (PK) profiles (rate and amount of nicotine absorbed) after a single use of the THS 2.2 Menthol (mTHS 2.2) compared to a single use of the menthol conventional cigarette (mCC) and nicotine nasal spray (NNS).</brief_summary>
	<brief_title>Nicotine Pharmacokinetic Profile and Safety of the Tobacco Heating System 2.2 Menthol (THS 2.2 Menthol)</brief_title>
	<detailed_description />
	<mesh_term>Nicotine</mesh_term>
	<mesh_term>Menthol</mesh_term>
	<criteria>Subject is aged from 22 to 65 years (inclusive). Smoking, healthy subject as judged by the Investigator. Subject smoked at least 10 commercially available menthol CCs per day (with brand restrictions) over the last 4 weeks. Subject has smoked for at least the last 3 consecutive years. As per Investigator judgment, the subject cannot participate in the study for any reason (e.g., medical, psychiatric, and/or social reason). Subject has received medication within 14 days or within 5 halflives of a drug (whichever is longer) which has an impact on CYP2A6 activity. Female subject is pregnant or breast feeding. Female subject does not agree to use an acceptable method of effective contraception.</criteria>
	<gender>All</gender>
	<minimum_age>22 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Smoking</keyword>
	<keyword>Nicotine absorption</keyword>
	<keyword>Candidate modified risk tobacco product</keyword>
	<keyword>Conventional cigarette</keyword>
	<keyword>Nicotine replacement therapy: nasal spray</keyword>
</DOC>